Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis y antigen

Gene Therapy

Volumn 17, Issue 5, 2010, Pages 678-686

  Peinert, S ^a   Prince, H M ^a,b   Guru, P M ^a   Kershaw, M H ^a   Smyth, M J ^a,b   Trapani, J A ^a,b   Gambell, P ^a   Harrison, S ^a   Scott, A M ^c   Smyth, F E ^c   Darcy, P K ^a   Tainton, K ^a   Neeson, P ^a   Ritchie, D S ^a,b   Honemann D ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

Acute myeloid leukemia; Immunotherapy; Multiple myeloma; T cells

Indexed keywords

BLOOD GROUP ANTIGEN; CARBOHYDRATE ANTIGEN; CD34 ANTIGEN; GAMMA INTERFERON; LE(Y) ANTIGEN; LEWIS Y ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP LEWIS SYSTEM; CANCER IMMUNOTHERAPY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MOUSE; MULTIPLE MYELOMA; MYELOBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR CELL DESTRUCTION;

ANIMALS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LEUKEMIA, MYELOID, ACUTE; LEWIS BLOOD-GROUP SYSTEM; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

MUS;

EID: 77952420345     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.21     Document Type: Article

References (44)

1. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelo-genous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
2. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
3. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hemato-poietic cells. J Clin Oncol 1999; 17: 208-215.
4. Burnett AK WK, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
5. Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodys-plastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006; 91: 1513-1522.
6. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hemato-poietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846.
7. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with auto-grafting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-1120.
8. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261-2271.
9. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A et al. Cytotoxic T lymphocyte therapy for Epstein-Barr Virus+ Hodgkin's disease. J Exp Med 2004; 200: 1623-1633.
10. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous anti-tumor lymphocytes. Proc Natl Acad Sci USA 2004; 101 (Suppl-2): 14639-14645.
11. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
12. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993; 178: 361-366.
13. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724.
14. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002; 100: 3155-3163.
15. Westwood JA, Smyth MJ, Teng MWL, Moeller M, Trapani JA, Scott AM et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 2005; 102: 19051-19056.
16. Power BE, Caine JM, Burns JE, Shapira DR, Hattarki MK, Tahtis K et al. Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. Cancer Immunol Immunother 2001; 50: 241-250.
17. Engels B, Uckert W. Redirecting T lymphocyte specificity by T cell receptor gene transfer\A new era for immunotherapy. Mol Aspects Med 2007; 28: 115-142.
18. Lamers CH, Gratama JW, Warnaar SO, Stoter G, Bolhuis RL. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer 1995; 60: 450-457.
19. Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE et al. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 2004; 11: 371-379.
20. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002; 169: 5780-5786.
21. Sakamoto J, Furukawa K, Cordon-Cardo C, Yin BWT, Rettig WJ, Oettgen HF et al. Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell Lines. Cancer Res 1986; 46: 1553-1561.
22. Kim YS, Yuan M, Itzkowitz SH, Sun Q, Kaizu T, Palekar A et al. Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res 1986; 46: 5985-5992.
23. Yin BWT, Finstad CL, Kitamura K, Federici MG, Welshinger M, Kudryashov Vet al. Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer 1996; 65: 406-412.
24. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II Blood group-related antigens. Int J Cancer 1997; 73: 50-56. (Pubitemid 27445990)
25. Miyake M, Taki T, Hitomi S, Hakomori S. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327: 14-28.
26. Cao Y, Merling A, Karsten U, Schwartz-Albiez R. The fucosy-lated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes. Glycobiology 2001; 11: 677-683.
27. Beran M PP, Kantarjian H, Porwit A, Bjorkholm M. Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice. Hematol Pathol 1994; 8: 135-154.
28. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, Santoli D. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 1992; 7: 827-836.
29. Kitamura K, Stockert E, Garin-Chesa P, Welt S, Lloyd KO, Armour KL et al. Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc Natl Acad Sci USA 1994; 91: 12957-12961.
30. Harrison SJ, Cook G, Nibbs RJ, Prince HM. Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Rev Anticancer Ther 2006; 6: 1769-1785.
31. Baldus SE, Palmen C, Thiele J. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma. Histol Histopathol 2007; 22: 889-893.
32. Schag K, Schmidt SM, Muller MR, Weinschenk T, Appel S, Weck MM et al. Identification of C-Met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res 2004; 10: 3658-3666.
33. Peinert S, Prince HM, Harrison S. The development of novel immunotherapeutic approaches in multiple myeloma. Leuk Lymphoma 2008; 49: 652-654.
34. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26: 332-342.
35. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002; 30: 1029-1035.
36. Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 2007; 67: 5489-5497.
37. Westwood JA, Murray WK, Trivett M, Shin A, Neeson P, MacGregor DP et al. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraft-ment in mice. Gene Therapy 2008; 15: 1056-1066.
38. Pai-Scherf LH, Carrasquillo JA, Paik C, Gansow O, Whatley M, Pearson D et al. Imaging and phase I study of 111In-and 90Y-labeled anti-LewisY monoclonal antibody B3. Clin Cancer Res 2000; 6: 1720-1730.
39. Scott AM, Tebbutt N, Lee F-T, Cavicchiolo T, Liu Z, Gill S et al. A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res 2007; 13: 3286-3292.
40. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D et al. Phase I trial of the Anti-Lewis Y drug immunoconjugate BR96-Doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18: 2282-2292.
41. Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE et al. Construction, production, and characterization of humanized Anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 2000; 60: 3254-3261.
42. Liu Z, Panousis C, Smyth FE, Murphy R, Wirth V, Cartwright G et al. Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses. Hybrid Hybridomics 2003; 22: 219-228.
43. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
44. Teng MWL, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. Immunotherapy of cancer using systemically delivered gene-modified human t lymphocytes. Hum Gene Ther 2004; 15: 699-708.